Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954263 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
A Phase 1 study of Healthy Adults, Elderly Subjects, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02954263: Completed Phase 1 study of Healthy Adults, Elderly Subjects, sponsored by Theravance Biopharma.
NCT02954263 is a Phase 1 study of Healthy Adults, Elderly Subjects that has completed, run by Theravance Biopharma. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02954263, a Phase 1 study of Healthy Adults, Elderly Subjects, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1439
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT02954263 record still lists
NCT02954263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Healthy Adults, Elderly Subjects appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02954263 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT02954263 about?
NCT02954263 is a clinical study titled "Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects". Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
What is the current status of trial NCT02954263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-11. Estimated completion is 2017-04.
What conditions does trial NCT02954263 study?
This clinical trial studies the following conditions: Healthy Adults, Elderly Subjects.
What interventions are being tested in trial NCT02954263?
The interventions under investigation include: Placebo (DRUG), TD-1439 (DRUG).
Who is sponsoring clinical trial NCT02954263?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02954263 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults, Elderly Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02954263's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia